Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 1, 2014, Pages 51-65

  Hu, Miao ^a   Tomlinson, Brian ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Drug interaction; Pharmacokinetics; Pitavastatin; Rosuvastatin; Statins

Indexed keywords

ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; CYCLOSPORIN; DARUNAVIR PLUS RITONAVIR; ERYTHROMYCIN; FLUCONAZOLE; FLUINDOSTATIN; GEMFIBROZIL; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR PLUS RITONAVIR; MEVINOLIN; PIOGLITAZONE; PITAVASTATIN; PRAVASTATIN; RIFAMPICIN; RITONAVIR; ROSUVASTATIN; SAQUINAVIR; SIMVASTATIN; TOLBUTAMIDE; TROGLITAZONE; URSOLIC ACID; WARFARIN;

ALCOHOL LIVER DISEASE; AREA UNDER THE CURVE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GLOMERULUS FILTRATION RATE; GRAPEFRUIT JUICE; HUMAN; IC 50; INTERNATIONAL NORMALIZED RATIO; KIDNEY CLEARANCE; KIDNEY FAILURE; LIPID DIET; LIVER CIRRHOSIS; MAXIMUM PLASMA CONCENTRATION; MEMBRANE PERMEABILITY; MYOPATHY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; REVIEW; RHABDOMYOLYSIS; SALVIA MILTIORRHIZA; SYSTEMATIC REVIEW; URINARY EXCRETION;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MODELS, ANIMAL; PYRIMIDINES; QUINOLINES; SULFONAMIDES;

EID: 84890363516     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.851667     Document Type: Review

References (157)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-Analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
2. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: A meta-Analysis of randomized trials. CMAJ 2008;178:576-84
3. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
4. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112:71-105
5. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol 2005;19:117-25
6. Garcia MJ, Reinoso RF, Sanchez Navarro A, Prous Jr. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 2003;25:457-81
7. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 2010;106:297-306
8. Catapano AL. Pitavastatin-pharmacological profile from early phase studies. Atheroscler Suppl 2010;11:3-7
9. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 2003;4:9-14
10. Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. Drugs 2002;62:2075-85; discussion 86-7
11. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract 2005;59:239-52
12. Kajinami K, Takekoshi N, Saito Y. Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2003;21:199-215
13. Simonson SG, Martin PD, Mitchell PD, et al. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 2005;45:927-34
14. Kowa Pharmaceuticals America, Inc. Livalo (pitavastatin) Package Insert (Version of October 2012). Montgomery, AL 36117, USA
15. AstraZeneca Pharmaceuticals LP. Crestor (rosuvastatin calcium) Package Insert: Revised 01/07. Wilmington, DE, USA
16. Hu M, Tomlinson B. Current Perspectives on rosuvastatin. Integr Blood Press Control 2013;6:15-25
17. Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003;25:2553-63
18. Crouse JR III. An evaluation of rosuvastatin: Pharmacokinetics, clinical efficacy and tolerability. Expert Opin Drug Metab Toxicol 2008;4:287-304
19. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002;54:472-7
20. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003;25:2822-35
21. Bellosta S, Paoletti R, Corsini A. Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109:III50-7
22. Reinoso RF, Sanchez Navarro A, Garcia MJ, Prous Jr. Preclinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 2002;24:593-613
23. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30:1280-7
24. Yamada I, Fujino H, Shimada S, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Similarities and difference in the metabolism of pitavastatin in monkeys and humans. Xenobiotica 2003;33:789-803
25. Kostapanos MS, Athyros VG, Karagiannis A, Mikhailidis DP. Therapeutic options for statin-intolerant patients. Curr Med Res Opin 2012;28:345-9
26. Martin PD, Dane AL, Nwose OM, et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: A new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002;42:1116-21
27. Tzeng TB, Schneck DW, Birmingham BK, et al. Population pharmacokinetics of rosuvastatin: Implications of renal impairment, race, and dyslipidaemia. Curr Med Res Opin 2008;24:2575-85
28. Bologa R, Levine D, Parker T, et al. Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis. Clin Nephrol 2009;72:437-41
29. Birmingham BK, Swan SK, Puchalski T, et al. Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis. Clin Drug Investig 2013;33:233-41
30. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407
31. Morgan RE, Campbell SE, Yu CY, et al. Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol 2012;60:42-8
32. Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 2006;109:1-11
33. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008;4:1065-74
34. Simonson SG, Martin PD, Mitchell P, et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol 2003;58:669-75
35. Hui CK, Cheung BM, Lau GK. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. Br J Clin Pharmacol 2005;59:291-7
36. Arai H, Yamamoto A, Matsuzawa Y, et al. Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000. J Atheroscler Thromb 2005;12:240-50
37. Brown WV. New therapies on the horizon. Am J Manag Care 2001;7:S148-51
38. Buckett L, Ballard P, Davidson R, et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atherosclerosis 2000;151:41
39. Malinowski HJ, Westelinck A, Sato J, Ong T. Same drug, different dosing: Differences in dosing for drugs approved in the United States, Europe, and Japan. J Clin Pharmacol 2008;48:900-8
40. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78:330-41
41. Tirona RG. Ethnic differences in statin disposition. Clin Pharmacol Ther 2005;78:311-16
42. Hu M, Lui SS, Ko GT, Tomlinson B. Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies. Int J Cardiol 2013;published online 1 May 2013; doi: Pii: S0167-5273(13)00675-X. 10.1016/j. ijcard.2013.04.091
43. Birmingham BK, Azumaya CT, Wei C, et al. Increased exposure levels of rosuvastatin, atorvastatin and simvastatin in Chinese and Japanese subjects: A class effect? Clin Pharmacol Ther 2008;83:S15
44. Warrington S, Nagakawa S, Hounslow N. Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: An open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men. Clin Drug Investig 2011;31:735-43
45. Ho RH, Tirona RG, Leake BF, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics. Gastroenterology 2006;130:1793-806
46. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 2008;36:2014-23
47. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004;311:139-46
48. Hirano M, Maeda K, Matsushima S, et al. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 2005;68:800-7
49. Huang L, Wang Y, Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 2006;34:738-42
50. Choi MK, Shin HJ, Choi YL, et al. Differential effect of genetic variants of Na(+)-Taurocholate co-Transporting polypeptide (NTCP) and organic anion-Transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica 2011;41:24-34
51. Fujino H, Saito T, Ogawa S, Kojima J. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol 2005;57:1305-11
52. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63:157-81
53. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008;9:19-33
54. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010;87:130-3
55. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-A genomewide study. N Engl J Med 2008;359:789-99
56. Hopewell JC, Offer A, Parish S, et al. Environmental and genetic risk factors for myopathy in Chinese partifipants from HPS2-THRIVE. European Society Cardiology. 2012. Available from: Http://www.thrivestudy.org/ ESC2012-THRIVE-myopathy-Abstract. pdf
57. Deng JW, Song IS, Shin HJ, et al. The effect of SLCO1B1.*15 on the disposition of pravastatin and pitavastatin is substrate dependent: The contribution of transporting activity changes by SLCO1B1.*15. Pharmacogenet Genomics 2008;18:424-33
58. Chung JY, Cho JY, Yu KS, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2005;78:342-50
59. Ieiri I, Suwannakul S, Maeda K, et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2007;82:541-7
60. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007;82:726-33
61. Choi JH, Lee MG, Cho JY, et al. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther 2008;83:251-7
62. Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 2010;10:1-11
63. Generaux GT, Bonomo FM, Johnson M, Doan KM. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica 2011;41:639-51
64. Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: Implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 2009;5:703-29
65. Hu M, Lui SS, Mak VW, et al. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet Genomics 2010;20:634-7
66. Thompson JF, Hyde CL, Wood LS, et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet 2009;2:173-81
67. Deshmukh HA, Colhoun HM, Johnson T, et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: Importance of Lp(a). J Lipid Res 2012;53:1000-11
68. Hopewell JC, Parish S, Offer A, et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur Heart J 2013;34:982-92
69. Chasman DI, Giulianini F, MacFadyen J, et al. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet 2012;5:257-64
70. Iusuf D, Sparidans RW, van Esch A, et al. Organic anion-Transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. Mol Pharm 2012;9:2497-504
71. Iusuf D, van Esch A, Hobbs M, et al. Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure. Mol Pharmacol 2013;83:919-29
72. Watanabe T, Kusuhara H, Maeda K, et al. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 2009;328:652-62
73. Mwinyi J, Johne A, Bauer S, et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004;75:415-21
74. Wen J, Xiong Y. OATP1B1 388A > G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J Clin Pharm Ther 2010;35:99-104
75. Hu M, Mak VW, Yin OQ, et al. Effects of grapefruit juice and SLCO1B1 388A G polymorphism on the pharmacokinetics of pitavastatin. Drug Metab Pharmacokinet 2013;28:104-8
76. Hu M, To KK, Mak VW, Tomlinson B. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin Drug Metab Toxicol 2011;7:49-62
77. Zhang W, Yu BN, He YJ, et al. Role of BCRP 421C > A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 2006;373:99-103
78. Keskitalo JE, Zolk O, Fromm MF, et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009;86:197-203
79. Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. Different effects of the ABCG2 c.421C > A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 2009;10:1617-24
80. Oh ES, Kim CO, Cho SK, et al. Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans. Drug Metab Pharmacokinet 2013;28:196-202
81. Tomlinson B, Hu M, Lee VW, et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther 2010;87:558-62
82. Keskitalo JE, Kurkinen KJ, Neuvonen M, et al. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol 2009;68:207-13
83. Zhou Q, Chen QX, Ruan ZR, et al. CYP2C9.*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics. Pharmazie 2013;68:187-94
84. Zhou Q, Ruan ZR, Yuan H, et al. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics. Pharmazie 2013;68:129-34
85. Becker ML, Elens LL, Visser LE, et al. Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. Pharmacogenomics J 2013;13:251-6
86. Lee HK, Hu M, Lui S, et al. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics 2013;14:1283-94
87. Degorter MK, Tirona RG, Schwarz UI, et al. Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentration in Routine Clinical Care. Circ Cardiovasc Genet 2013;6:400-8
88. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90
89. Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf 2012;11:933-46
90. Bottorff MB. Statin safety and drug interactions: Clinical implications. Am J Cardiol 2006;97:27C-31C
91. Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): The importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 2010;11:323-32
92. Laszlo A, Kalabay L, Nemcsik J. Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: Contradictions between the two main therapeutic pathways. BMC Res Notes 2013;6:52
93. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81
94. Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between hmg-coa reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet 2013;published online 24 May 2013; doi: 10.1007/s40262-013-0075-4
95. Corsini A, Ceska R. Drug-drug interactions with statins: Will pitavastatin overcome the statins' Achilles' heel? Curr Med Res Opin 2011;27:1551-62
96. Toth PP, Dayspring TD. Drug safety evaluation of rosuvastatin. Expert Opin Drug Saf 2011;10:969-86
97. Ose L. Pitavastatin: Finding its place in therapy. Ther Adv Chronic Dis 2011;2:101-17
98. Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-Associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 2010;10:11-28
99. van de Steeg E, Greupink R, Schreurs M, et al. Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1. Drug Metab Dispos 2013;41:592-601
100. Hua WJ, Hua WX, Fang HJ. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins. Cardiovasc Ther 2012;30:e234-41
101. Frishman WH, Horn J. Statin-drug interactions: Not a class effect. Cardiol Rev 2008;16:205-12
102. Josephson F. Drug-drug interactions in the treatment of HIV infection: Focus on pharmacokinetic enhancement through CYP3A inhibition. J Intern Med 2010;268:530-9
103. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998;64:58-65
104. Cooper KJ, Martin PD, Dane AL, et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 2003;55:94-9
105. Cooper KJ, Martin PD, Dane AL, et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003;73:322-9
106. Cooper KJ, Martin PD, Dane AL, et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002;58:527-31
107. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002;16:569-77
108. Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol 2012;52:922-31
109. Morgan RE, Campbell SE, Suehira K, et al. Effects of steady-state lopinavir/ ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr 2012;60:158-64
110. Cooper KJ, Martin PD, Dane AL, et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003;59:51-6
111. Launay-Vacher V, Izzedine H, Deray G. Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol 2005;101:9-17
112. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004;76:167-77
113. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-Treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997;62:311-21
114. Hasunuma T, Nakamura M, Yachi T, et al. The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J Clin Ther Med 2003;19:381-9
115. Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 2005;96:44K-9K; discussion 34K-35K
116. Jacobson TA. Myopathy with statin-fibrate combination therapy: Clinical considerations. Nat Rev Endocrinol 2009;5:507-18
117. Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: Review of 76 published cases and a new case report. Eur J Clin Pharmacol 2009;65:1169-74
118. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004;75:455-63
119. Fujino H, Saito T, Tsunenari Y, Kojima J. Effect of gemfibrozil on the metabolism of pitavastatin-determining the best animal model for human CYP and UGT activities. Drug Metabol Drug Interact 2004;20:25-42
120. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63:397-402
121. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477-83
122. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999;66:118-27
123. Eagling VA, Profit L, Back DJ. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 1999;48:543-52
124. Rebello S, Zhao S, Hariry S, et al. Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects. Eur J Clin Pharmacol 2012;68:697-708
125. Shirasaka Y, Suzuki K, Nakanishi T, Tamai I. Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein. J Pharm Sci 2011;100:3843-53
126. Ando H, Tsuruoka S, Yanagihara H, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 2005;60:494-7
127. Fukazawa I, Uchida N, Uchida E, Yasuhara H. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol 2004;57:448-55
128. Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007;81:194-204
129. Vavricka SR, Van Montfoort J, Ha HR, et al. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002;36:164-72
130. Baldes C, Koenig P, Neumann D, et al. Development of a fluorescence-based assay for screening of modulators of human organic anion transporter 1B3 (OATP1B3). Eur J Pharm Biopharm 2006;62:39-43
131. Kyrklund C, Backman JT, Kivisto KT, et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000;68:592-7
132. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005;78:154-67
133. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2004;57:181-7
134. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001;40:263-81
135. Chen Y, Zhang W, Huang WH, et al. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers. Eur J Clin Pharmacol 2013;published online 7 July 2013; doi: 10.1007/s00228-013-1554-0
136. Zhang W, Deng S, Chen XP, et al. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: A randomized, single-blind, placebo-controlled, crossover study. Clin Ther 2008;30:1283-9
137. Andrus MR. Oral anticoagulant drug interactions with statins: Case report of fluvastatin and review of the literature. Pharmacotherapy 2004;24:285-90
138. Yu CY, Campbell SE, Zhu B, et al. Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin. Curr Med Res Opin 2012;28:187-94
139. Andersson ML, Eliasson E, Lindh JD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9.*3 allele. Pharmacogenomics 2012;13:757-62
140. Inagaki Y, Hunt T, Arana B, et al. Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers. J Clin Pharmacol 2011;51:1302-9
141. Wen JH, Xiong YQ. The effect of herbal medicine danshensu and ursolic acid on pharmacokinetics of rosuvastatin in rats. Eur J Drug Metab Pharmacokinet 2011;36:205-11
142. Basu S, Jana S, Patel VB, Patel H. Effects of piperine, cinnamic acid and gallic acid on rosuvastatin pharmacokinetics in rats. Phytother Res 2012;published online 3 December 2012; doi: 10.1002/ptr.4894
143. Fan L, Zhang W, Guo D, et al. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-Transporting polypeptide 1B1. Clin Pharmacol Ther 2008;83:471-6
144. He YJ, Zhang W, Tu JH, et al. Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. Drug Metab Dispos 2008;36:1453-6
145. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006;34:1229-36
146. Yamashiro W, Maeda K, Hirouchi M, et al. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 2006;34:1247-54
147. Jung JA, Noh YH, Jin S, et al. Pharmacokinetic interaction between pitavastatin and valsartan: A randomized, open-labeled crossover study in healthy male Korean volunteers. Clin Ther 2012;34:958-65
148. Soran H, Durrington P. Rosuvastatin: Efficacy, safety and clinical effectiveness. Expert Opin Pharmacother 2008;9:2145-60
149. Ferdinand KC. Rosuvastatin: A risk-benefit assessment for intensive lipid lowering. Expert Opin Pharmacother 2005;6:1897-910
150. Teramoto T. The clinical impact of pitavastatin: Comparative studies with other statins on LDL-C and HDL-C. Expert Opin Pharmacother 2012;13:859-65
151. Kawai Y, Sato-Ishida R, Motoyama A, Kajinami K. Place of pitavastatin in the statin armamentarium: Promising evidence for a role in diabetes mellitus. Drug Des Devel Ther 2011;5:283-97
152. Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: Implications for risk assessment, prevention and treatment. Drug Saf 2010;33:171-87
153. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: A systematic overview of randomized clinical trials. Circulation 2006;114:2788-97
154. Catapano AL. Statin-induced myotoxicity: Pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Curr Vasc Pharmacol 2012;10:257-67
155. Hu M, Mak VWL, Chu TTY, et al. Pharmacogenetics of HMG-CoA reductase inhibitors: Optimizing the prevention of coronary heart disease. Curr Pharmacogenomics Personalized Med 2009;7:1-26
156. Hegedus C, Szakacs G, Homolya L, et al. Ins and outs of the ABCG2 multidrug transporter: An update on in vitro functional assays. Adv Drug Deliv Rev 2009;61:47-56
157. Rodrigues AC, Hirata MH, Hirata RD. Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs. Pharmacogenomics 2009;10:1007-16